The Washington Post Reports That DEA Claims It Seized Enough Fentanyl to Kill Us All

While Law Enforcement Address Supply Issues, GATC Health Joins Fight Against Demand With Novel Addiction Treatments

Of the 107,000 people who died from overdose in the US in 2022, 75% died from a synthetic opioid like fentanyl. The epidemic is not slowing, but a concerted effort by law enforcement to stem supply and policymakers to create and fund adequate intervention, treatment and rehabilitation programs could help.

GATC Health joined this effort with a new and powerful therapeutic to treat fentanyl addiction. GATC’s Multiomic Advanced Technology™ platform (MAT) has discovered novel addiction drug candidates which are currently in advanced pre-clinical studies to assess the specificity, safety, and toxicity to assure low toxicity overall and safety for use in humans, while increasing the opportunity for success in human clinical trials. These studies should prove that GATC's fentanyl addiction treatment reverses the effects of addiction on the brain, effectively "rewiring" it to a more normal, healthier state. While current treatment protocols often include substituting a drug like methadone for fentanyl or heroin, GATC's addiction abatement drug candidate could be the first instance of a non-opioid treatment for opioid use disorder (OUD), effectively reducing demand for these dangerous drugs.

Source: The Washington Post